Loading
NASDAQHealthcareBiotechnology
Latest quote
$14.39
−$0.26 · -1.77%
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Previous close
$14.39
−$0.26 · -1.77%
Regular session · ET · Market data may be delayed.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Day range
Current $14.39
52-week range
Current $14.39
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
40
Expensive
Sentiment
71
Bullish
Risk
53
Elevated Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Day range
Current $14.39
52-week range
Current $14.39
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 105K USD | — | — | — | — |
| Gross profit | −105K USD | — | — | — | — |
| Research and development | 33.72M USD | 19.39M USD | 16.53M USD | 24.47M USD | 29.12M USD |
| Selling, general, and administrative | 9.25M USD | 8.16M USD | 6.88M USD | 8.1M USD | 9.52M USD |
| Operating expenses | 42.87M USD | 27.55M USD | 23.41M USD | 32.57M USD | 38.63M USD |
| Interest income | 2.51M USD | 1.82M USD | 1.58M USD | 654K USD | — |
| Interest expense | — | — | — | — | 15K USD |
| Depreciation and amortization | 105K USD | 85K USD | 151K USD | 367K USD | 460K USD |
| Operating income | −42.97M USD | −27.55M USD | −23.41M USD | −32.57M USD | −38.63M USD |
| Net income | −15.28M USD | −62.29M USD | −27.03M USD | −41.31M USD | −43.24M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$40.00
177.97% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI45.8M0.40%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI31.92M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM24.89M0.03%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF11.32M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO9.02M0.06%14.58B USD0.24%$377.54+0.12%
iShares Biotechnology ETFIBB6.66M0.06%10.72B USD0.44%$211.92-0.88%
Vanguard Russell 2000 ETFVTWO5.03M0.03%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC3.29M0.23%1.47B USD0.60%$196.25+0.69%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
